Related Experiment Video
Updated: Nov 11, 2025

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
Published on: July 8, 2025
Neuroleptic malignant syndrome associated with the use of injection zuclopenthixol acetate
Anish Shouan1, Ankit Kumar Sinha1, Sandeep Grover1
1Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Abstract:
Zuclopenthixol is available in two parenteral formulation,i.e., in the form of acetate and decanoate. It has high affinity for dopamine D1 and D2 receptors. There is limited literature of association of neuroleptic malignant syndrome with the use of zuclopenthixol monotherapy. These case reports have mostly implicated zuclopenthixol decanoate, and also zuclopenthixol acetate. In this report, we present a case of neuroleptic malignant syndrome associated with use of zuclopenthixol acetate.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Psychosis: Goals of Pharmacotherapy
Depolarizing Blockers: Pharmocokinetics
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Antipsychotic Drugs: Typical and Atypical Agents

